Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease (TDPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04002596
Recruitment Status : Recruiting
First Posted : June 28, 2019
Last Update Posted : June 28, 2019
Sponsor:
Information provided by (Responsible Party):
InSightec

Brief Summary:
Safety and Effectiveness in ExAblate Neuro treatment of medication-refractory tremor in subjects with idiopathic Parkinson's disease.

Condition or disease Intervention/treatment Phase
Parkinson Disease Device: ExAblate Neuro Thalamotomy Treatment Not Applicable

Detailed Description:

The goal of this prospective, single-arm, multi-site, feasibility study is to develop data to evaluate the safety and effectiveness of unilateral focused ultrasound thalamotomy using this ExAblate Transcranial System in the treatment of medication-refractory tremor resulting from idiopathic Parkinson's disease.

The Indications for Use claim for this system is: treatment of medication-refractory tremor in subjects with idiopathic Parkinson's disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: ExAblate Neuro Treatment Group
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
Actual Study Start Date : February 6, 2017
Estimated Primary Completion Date : August 30, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ExAblate MRgFUS treatment
Ablation of Thalamus Vim nucleus with ExAblate 4000 Neuro MRgFUS for TDPD
Device: ExAblate Neuro Thalamotomy Treatment
Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
Other Names:
  • MRgFUS Vim ablation
  • Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus




Primary Outcome Measures :
  1. Clinical Rating Scale for Tremor [ Time Frame: 3 Months after Treatment ]
    Primary effectiveness will be a comparison of the CRST scores at baseline vs. 3 months. (Range 0-152, scores are combined, the higher the score, the greater the clinical level of tremor, the worse clinical outcome is)

  2. Severity of Device and Procedure related complications [ Time Frame: 1 year ]
    To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor dominant PD after the ExAblate treatment and during the follow-up period of up up to 1 year


Secondary Outcome Measures :
  1. Clinical Rating Scale for Tremor, Total Score [ Time Frame: 1 year ]
    On-medication, total tremor (CRST) score (Range 0-152, scores are combined, the higher the score, the greater the clinical level of tremor, the worse clinical outcome is)

  2. Clinical Rating Scale for Tremor, Part C [ Time Frame: 1 year ]
    Level of disability measured from Part C subsection of CRST - Subcore of sections 16 to 23 (Range 0-32, scores are combined, the higher the scub-score, the greater the level of subject's disability, the worse clinical outcome is)

  3. Parkinson's Disease Questionnaire - 39 [ Time Frame: 1 year ]
    Quality of life assessment with PDQ-39 (Range 0-156, scores are combined, the higher the score, the greater the level of clinical expression of Parkinson Disease, the worse clinical outcome is)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women, age 30 years and older
  2. Subjects who are able and willing to give informed consent and able to attend all study visits through 3 Months
  3. Subjects with a diagnosis of idiopathic PD as confirmed from clinical history and examination by a movement disorder neurologist at the site
  4. All subjects included in this study will have a TD/PIGD ratio > 1.15 in the medicated [ON] state as calculated from the UPDRS formula as described by S, et. al., [74].

    Note: Ratios for TD/PIGD that are greater than or equal to 1.15 are defined as TDPD. PIGD includes those with a ratio of less than or equal to 0.9. Scores of greater than 0.9 and less than 1.15 are considered a mixed subtype.

  5. Subject demonstrates a resting tremor severity score of greater than or equal to 3 in the hand/arm as measured by the medicated (ON) MDS-UPDRS question 3.17 or a postural/action tremor greater than or equal to a 2 for question 3.15 or 3.16.
  6. Significant disability due to PD tremor despite medical treatment (CRST score of 2 or above in any one of the items 16-23 from the Disability subsection of the CRST: [speaking, feeding other than liquids, bringing liquids to mouth, hygiene, dressing, writing, working, and social activities])
  7. Tremor remains disabling when medical therapy is optimal or not tolerated for the treatment of other cardinal signs of PD (bradykinesia, rigidity, etc), as determined by a movement disorders neurologist at the site
  8. Subjects should be on a stable dose of all PD medications for 30 days prior to study entry.
  9. The thalamus must be apparent on MRI such that targeting of the Vim nucleus can be performed indirectly by measurement from a line connecting the anterior and posterior commissures of the brain.
  10. Subject is able to communicate sensations during the ExAblate Transcranial procedure.

Exclusion Criteria:

  1. Subjects with unstable cardiac status including:

    1. Unstable angina pectoris on medication
    2. Subjects with documented myocardial infarction within six months of protocol entry
    3. Significant congestive heart failure defined with ejection fraction < 40
    4. Subjects with unstable ventricular arrhythmias
    5. Subjects with atrial arrhythmias that are not rate-controlled
  2. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the following occurring within the preceding 12 month period:

    1. Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household).
    2. Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use)
    3. Recurrent substance-related legal problems (such as arrests for substance related disorderly conduct)
    4. Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights).
  3. Severe hypertension (diastolic BP > 100 on medication)
  4. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  5. Significant claustrophobia that cannot be managed with mild medication.
  6. Current medical condition resulting in abnormal bleeding and/or coagulopathy
  7. Patient with severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis;
  8. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure
  9. Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter, a documented clinical coagulopathy, or INR coagulation studies exceeding the institution's laboratory standard
  10. History of intracranial hemorrhage
  11. History of multiple strokes, or a stroke within past 6 months
  12. Subject who weigh more than the upper weight limit of the table or subjects who will not fit into the MR scanner
  13. Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment.
  14. Are participating or have participated in another clinical trial in the last 30 days
  15. Subjects unable to communicate with the investigator and staff.
  16. Presence of central neurodegenerative disease, including but not limited to Parkinson-plus syndromes, suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.
  17. Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.
  18. Presence of significant cognitive impairment as determined with a score ≤ 24 on the Mini Mental Status Examination (MMSE)
  19. Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation. Subjects with stable, chronic anxiety or depressive disorders may be included provided their medications have been stable for at least 60 days prior to study entry and if deemed appropriately managed by the site neuropsychologist
  20. Subjects with significant depression as determined following a comprehensive assessment by a neuropsychologist. Significant depression is being defined quantitatively as a score of greater than 14 on the Beck Depression Inventory.
  21. Legal incapacity or limited legal capacity as determined by the neuropsychologist
  22. Subjects with a history of seizures within the past year
  23. Subjects with brain tumors
  24. Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment.
  25. Any illness that in the investigator's opinion preclude participation in this study.
  26. Pregnancy or lactation.
  27. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia
  28. Subjects with remarkable atrophy and poor healing capacity of the scalp (> 30% of the skull area traversed by the sonication pathway) will be excluded from this study
  29. Subjects who have an Overall Skull Density Ratio of 0.30 (±0.05) or less as calculated from the screening CT.

    • It should be noted that for those candidates whose SDR ratio score is within the standard deviation, full technical assessment should be performed and reviewed by study investigator with the support of the sponsor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04002596


Contacts
Layout table for location contacts
Contact: Maritn Bernstein +97248131268 martinb@insightec.com

Locations
Layout table for location information
China, Henan
Henan Provincial Peoples Hospital Recruiting
Zhengzhou, Henan, China
Contact: Yan Bai, MD    +86-18838277756    zhaodedao@sina.com   
Principal Investigator: Meiyun Wang, Prof.         
Japan
Shonan Fujisawa Tokushukai Hospital Recruiting
Fujisawa, Kanagawa, Japan
Contact: Etsuko Shimizu    +81-466-35-1177    shimizu@mirai-iryo.com   
Principal Investigator: Tetsumasa Kamei, MD         
Sub-Investigator: Hisashi Ito, MD         
Sub-Investigator: Shigeru Fukutake, MD         
Sub-Investigator: Kazuaki Yamamoto, MD         
Sponsors and Collaborators
InSightec
Investigators
Layout table for investigator information
Study Director: Martin Bernstein InSightec
Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT04002596    
Other Study ID Numbers: PD001J
First Posted: June 28, 2019    Key Record Dates
Last Update Posted: June 28, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases